IL18 and leukemia: In parallel, we demonstrated that 4th-gen CAR design by integration of new modalities such as IL-18 can strengthen the functional performance of healthy donor and leukaemia patient-derived CAR T cells, which holds promise for patients with leukaemia, especially those whose 2nd-gen CAR T cell products fail to generate robust anti-leukaemia responses.